News bites: Amazon Pharmacy’s same-day delivery zooms, One Medical’s lab results app, OpenEvidence’s valuation shock, NYU Langone-Isaac Health, HealthMark buys Purview, Harbor Health buys Rippl, big raises for Solace Health, Talkiatry

February 13, 2026 | by

Amazon Pharmacy growing same-day prescription delivery to 6,500 cities and towns by end of 2026. This adds nearly 2,000 locations. Amazon currently delivers to all 50 states and DC with either same day or next day delivery. Same day is adding locations in two new states, Idaho and Massachusetts. The release rather amusingly lists the horses they use on Mackinac Island, Michigan (no cars or e-anything), e-bikes in Manhattan, EVs in the suburbs, and One Medical kiosks in Los Angeles, which debuted last October. Amazon also touted their savings outside of insurance, an item much in the news with TrumpRx.com–up to 80% on generic medications and 40% on brand-name medications through Prime Rx at no additional cost. What does this mean for telehealth competition? A drop in stock price for Teladoc, Hims & Hers (added to by a GLP-1 pill patent infringement suit by Novo Nordisk), and battered Doximity (Doximity Dialer). Yahoo Finance, TechCrunch  

Amazon’s clinic network, One Medical, premiers a ‘beta feature’ that analyzes personal lab results. The Health Insights feature, developed in partnership with Lifeforce, is on the Lab Results tab. After answering a questionnaire, the patient can see an AI-generated:

  • Personalized wellness score based on their biomarker profile
  • Detailed analysis of individual biomarkers categorized by health domain
  • Evidence-based lifestyle recommendations around nutrition, physical activity, stress management, and sleep
  • Scientific references supporting each recommendation

This Editor noted that One Medical is gradually transitioning to an Amazon identity and logotype. Release

Shocked, shocked at OpenEvidence’s $12 billion valuation? According to Katie Adams in MedCityNews, mais non. We noted at the end of January, when OpenEvidence collected $250 million in a Series D, that it was this year’s “hot number”. Certainly it’s “IT” with the docs as a reference source, claiming daily average usage by 40% of US doctors in 10,000 hospitals and medical centers. More than 757,000 clinicians use their free search engine trained on journals and clinical medical data only, coupled with an AI chatbot agent. It does a job that Doximity, Epocrates, and Medscape aren’t doing. It also dispenses with going through organizations as it permits direct signup. Pharma likes the model and votes with its shrinking dollars, giving OpenEvidence a $100 million revenue run rate. So do investors, who’ve socked $700 million into the company since 2021. There’s nothing like being the ‘up and comer’, as was said on a recent analyst call this Editor was on.

Isaac Health partners with NYU Langone for virtual dementia care. The NYC-based health system, with a strong base in neurology and brain health, seeks to reduce the time for a referral and testing for cognitive impairments. With Isaac, the patient is scheduled quickly, usually within a week, for a virtual consult. Isaac is integrated with NYU Langone’s systems to combine virtual with in-person care. If the patient is not comfortable with technology or the visit, a trained helper can be sent to the home to help manage the virtual visit. Isaac release,  MedCityNews

M&A and raises, in contrast to 2025, remain busy

HealthMark Group buys Purview. Purview’s cloud-based systems provide quick access to ingestion, analysis and sharing of medical imaging data, providing access to imaging records quickly. HealthMark Group is a provider of clinical information exchange solutions for healthcare providers. Acquisition cost was not disclosed, but Annapolis MD based Purview is listed as having less than 10 employees on Crunchbase with no funding listed, while HealthMark Group was refinanced last July by TA Associates private equity, retaining an interest from Ridgemont Equity Partners.   Release, 

Austin, Texas-based Harbor Health is acquiring dementia care platform Rippl. Harbor Health combines a clinic network in Texas with health plans. Most of the clinics are in Austin with expansion to El Paso, San Antonio, and Dallas via last year’s acquisition of 32 VillageMD clinics [TTA 9 October 2025]. Rippl’s platform is designed to support care at home for those with dementia via early detection of physical and behavioral issues. Rippl is also obtaining additional financing from seven investors including General Catalyst and Google Ventures. Acquisition cost was not disclosed. Harbor Health release

And to close, two hefty later-stage raises:

  • Solace Health notched a surprising $130 million Series C. It provides healthcare navigation via advocates for patients requiring guidance on a new diagnosis, needing referrals, understanding insurance coverage, and care coordination. Costs are covered by Medicare, most Medicare Advantage plans and some health insurance carriers. The round was led by IVP, with participation from Menlo Ventures, SignalFire, Torch Capital, Inspired Capital and RiverPark Ventures. This topped last year’s $60 million Series B for a total $211 million financing since 2021. Valuation entered unicorn territory of over $1 billion. MedCityNews, Mobihealthnews 
  • Talkiatry raised $210 million in a Series D, but presently no plans for an IPO. Their total financing now tops $400 million. Talkiatry was an early entrant (2019) in virtual psychiatry and therapy, and employs over 800 psychiatrists and 300 therapists, delivering 3 million patient visits to date. Another asset is that it is in-network with over 100 payers. The round was led by Perceptive Advisors with four other participants. MedCityNews

Industry news short takes: fundings for Qure.AI, Centivo, Rippl, Surescripts; M&A closings for GE Healthcare-Intelligent Ultrasound, LetsGetChecked-Truepill. And is Hinge Health going public soon?

October 3, 2024 | by

The waning days of summer wrapped with a few moderate-sized fundings:

India’s Qure.AI scored a $65 million Series D, bringing their total funding to $125 million. Leading the raise: Lightspeed and 360 ONE Asset, followed by Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, Health Quad, and TeamFund. Qure.AI uses AI to analyze radiology images and ultrasound scans, against billions of clinical image datasets. It currently is used in over 90 countries and 3,100 locations including NHS Trusts. While headquartered in India, Qure.AI has international HQs in NYC, London, and Dubai. The fresh funding will be used to expand its US presence, invest in foundational AI models, and interestingly, acquire medtech companies. Another emphasis of the company is to expand skilled radiology to locations which are resource-constrained, such as healthcare facilities in developing nations or in global rural areas. It is also being used in clinical trials by Johnson & Johnson, Astra Zeneca, and Viatris. MedCityNews 

Centivo added $75 million in equity and debt financing, bringing their total funding to $226.4 million. Centivo provides a primary-care centered health plan directly to employers in all 50 states by partnering with local health systems and direct contracts with ACOs in 18 markets. Centivo replaces traditional health plan and broker relationships. What they offer to employers is an advanced primary care centered model through Centivo Care, an in-house virtual primary care practice. They claimed as of 2023 results of 71% reduction in member out-of-pocket costs compared to commercial plans offered to employers, saving employers 15% or more, and increasing utilization of primary and specialty care. Whether this will “fix America’s broken healthcare model” (a meme we’ve heard many times before) is debatable, but the siren song of reduced healthcare costs for employers is evidently attractive to a raft of funders. It attracted new strategic investors Cone Health Ventures and MemorialCare Innovation Fund, plus existing financial investors including B Capital, Cox Enterprises, F-Prime Capital, Ingleside Investors, and Morgan Health (a division of JPMorgan Chase). Debt financing was provided by Trinity Capital and ongoing banking partner, JPMorgan Chase.  Release, Mobihealthnews, MedCityNews

It’s a $23 million Series A for Rippl to advance virtual on-demand dementia and senior-focused behavioral care. The new funding will be used to expand the company’s geographic footprint, currently Washington, Texas, Illinois, and Missouri, to California, Florida, and Arizona. The company’s key partners are the Alzheimer’s Association, Medicare Advantage Plans, ACOs and other payors and payviders. Rippl is also a participant in the Centers for Medicare & Medicaid Services’ (CMS) eight-year alternative payment model, the Guiding an Improved Dementia Experience Model (GUIDE Model). It started in July with 390 healthcare providers. The Series A was led by Tina Hoang-To, Kin Ventures Founding General Partner, with participation from Rippl’s seed investors ARCH Venture Partners, General Catalyst, GV (Google Ventures), F-Prime, Mass General Brigham Ventures, and 1843 Capital. JSL Health also joined the round. Release 

E-prescriber Surescripts now has a majority investment from private equity TPG Capital. The investment amount was not disclosed and regulatory approval is pending. Its current ownership is 50% by the National Community Pharmacies Association and the National Association of Chain Drug Stores, with the other half Express Scripts and CVS Caremark. It was not disclosed how the ownership shares would be adjusted among the five entities, as CEO Frank Harvey said that all will remain. Surescripts brought in Triple Tree to explore a sale back in April. This Editor noted then that Surescripts has about 95% of the e-prescribing market, enabling it to obfuscate their real business in the vagueness of “health intelligence sharing”. Certainly the PBM owners can use the cash, if cash they’ll get. Release, FierceHealthcare 

Closing M&A deals kick off the fall:

On Tuesday, GE Healthcare closed their $51 million purchase of Intelligent Ultrasound’s clinical AI business [TTA 25 July]. Intelligent already partnered with GEHC on its ScanNav Assist AI technology to power its SonoLystlive and SonoLyst X/IR for GEHC’s Voluson Expert and Voluson Signature ultrasound devices, plus the Voluson Swift. GEHC plans to incorporate Intelligent’s solutions across its ultrasound portfolio through improving workflows and enhancing ease of use for clinicians and patients. MassDevice

And the Optum-arranged ‘marriage’ of LetsGetChecked and Truepill wasted no time in closing on Tuesday. Truepill, a digital/mail order pharmacy, will operate as a subsidiary of LetsGetChecked, an at-home diagnostic with testing kits. Earlier reports indicated that Truepill would be the surviving entity.  Both companies have substantial investments from Optum Ventures and have been losing money for years. Truepill was caught up in the Cerebral and Done Health Schedule II as a fulfillment pharmacy for both and fell under DEA scrutiny with a ‘show cause’ action. TTA extensively analyzed the structure of the “$525 million” acquisition by LGC and the Optum role in it at the time of the announcement TTA 22 August. Interestingly, the closing announcement does not reiterate the acquisition cost. Release, Mobihealthnews

Will virtual MSK provider Hinge Health go public soon? Blake Madden in his Hospitalogy blog 1 October confirms that Morgan Stanley has been hired to run the long-rumored IPO process. Undoubtedly, their management is looking at Sword Health’s nifty recent raise and $3 billion valuation. Investors have been pushing for an exit for some time. In April, the last time that Hinge was on the TTA radar, it had cut 10% of its 1,700 employees yet at that time was rumored to be considering an IPO. Hinge’s last raise was an October 2021 $400 million Series E led by Tiger Global and Coatue Management for a total funding of $826.1 million over 10 raises (Crunchbase). At that time, their valuation was a bubbly $6.2 billion, which despite $400 million in cash reserves (as of April) and its popular niche, in today’s market would be drastically revised downward. Stay tuned….